- Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Samaan JS, Ng WH
- KMID: 2544003
- Clin Mol Hepatol.
- 2023 Jul;29(3):823-824.
- doi: 10.3350/cmh.2023.0182
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Samaan JS, Ng WH
- KMID: 2544002
- Clin Mol Hepatol.
- 2023 Jul;29(3):821-822.
- doi: 10.3350/cmh.2023.0183
-
- CITED
-
- Close
- SHARE
-
- Close
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
-
Lee SK, Kwon JH
- KMID: 2544004
- Clin Mol Hepatol.
- 2023 Jul;29(3):825-827.
- doi: 10.3350/cmh.2023.0185
-
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines for management of autoimmune hepatitis 2022
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2543981
- Clin Mol Hepatol.
- 2023 Jul;29(3):542-592.
- doi: 10.3350/cmh.2023.0087
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
-
Emiroglu HH
- KMID: 2543997
- Clin Mol Hepatol.
- 2023 Jul;29(3):812-812.
- doi: 10.3350/cmh.2023.0132
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Kleebayoon A, Wiwanitkit V
- KMID: 2543999
- Clin Mol Hepatol.
- 2023 Jul;29(3):815-816.
- doi: 10.3350/cmh.2023.0170
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Ali H
- KMID: 2543998
- Clin Mol Hepatol.
- 2023 Jul;29(3):813-814.
- doi: 10.3350/cmh.2023.0120
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]
-
Oh JH, Sinn DH
- KMID: 2544005
- Clin Mol Hepatol.
- 2023 Jul;29(3):828-829.
- doi: 10.3350/cmh.2023.0054e
-
- CITED
-
- Close
- SHARE
-
- Close
- The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
-
Mao X, Mak LY, Seto WK
- KMID: 2543987
- Clin Mol Hepatol.
- 2023 Jul;29(3):690-692.
- doi: 10.3350/cmh.2023.0173
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
-
Oh JH, Sinn DH
- KMID: 2544001
- Clin Mol Hepatol.
- 2023 Jul;29(3):820-820.
- doi: 10.3350/cmh.2023.0135
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
-
Jeong S, Lim Y, Lee SK, Han HW
- KMID: 2543996
- Clin Mol Hepatol.
- 2023 Jul;29(3):810-811.
- doi: 10.3350/cmh.2023.0129
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
-
Han SK, Baik SK, Kim MY
- KMID: 2544000
- Clin Mol Hepatol.
- 2023 Jul;29(3):817-819.
- doi: 10.3350/cmh.2023.0155
-
- CITED
-
- Close
- SHARE
-
- Close
- Acute-on-chronic liver failure: Terminology, mechanisms and management
-
BR VK, Sarin SK
- KMID: 2543986
- Clin Mol Hepatol.
- 2023 Jul;29(3):670-689.
- doi: 10.3350/cmh.2022.0103
Acute-on-chronic liver failure is an acute deterioration of liver function manifesting as jaundice and coagulopathy with the development of ascites, with a high probability of extrahepatic organ involvement and high... -
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]
-
Kim KA, Lee S, Park HJ, Jang ES, Lee YJ, Cho SB, Kim YS, Kim IH, Lee BS, Chung WJ, Ahn SH, Kim S, Jeong SH
- KMID: 2544006
- Clin Mol Hepatol.
- 2023 Jul;29(3):830-830.
- doi: 10.3350/cmh.2022.0345e
-
- CITED
-
- Close
- SHARE
-
- Close
- Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
-
Iwamoto H, Shimose S, Shirono T, Niizeki T, Kawaguchi T
- KMID: 2543982
- Clin Mol Hepatol.
- 2023 Jul;29(3):593-604.
- doi: 10.3350/cmh.2022.0391
Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective... -
- CITED
-
- Close
- SHARE
-
- Close
- Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association
-
Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H, Research Committee of the Korean Liver Cancer Association
- KMID: 2543980
- Clin Mol Hepatol.
- 2023 Jul;29(3):521-541.
- doi: 10.3350/cmh.2023.0202
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established... -
- CITED
-
- Close
- SHARE
-
- Close
- A decade of liver organoids: Advances in disease modeling
-
Liu Y, Sheng JY, Yang CF, Ding J, Chan YS
- KMID: 2543985
- Clin Mol Hepatol.
- 2023 Jul;29(3):643-669.
- doi: 10.3350/cmh.2022.0428
Liver organoids are three-dimensional cellular tissue models in which cells interact to form unique structures in culture. During the past 10 years, liver organoids with various cellular compositions, structural features,... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
-
Yeo YH, Samaan JS, Ng WH, Ting PS, Trivedi H, Vipani A, Ayoub W, Yang JD, Liran O, Spiegel B, Kuo A
- KMID: 2543990
- Clin Mol Hepatol.
- 2023 Jul;29(3):721-732.
- doi: 10.3350/cmh.2023.0089
Background/Aims: Patients with cirrhosis and hepatocellular carcinoma (HCC) require extensive and personalized care to improve outcomes. ChatGPT (Generative Pre-trained Transformer), a large language model, holds the potential to provide professional... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
-
Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, Han NX, Fong KY, Chen E, Wong C, Rui F, Xu X, Xue Q, Hu XY, Leow WQ, Goh GBB, Cheung R, Wong G, Wong VWS, Yu MW, Nguyen MH
- KMID: 2543989
- Clin Mol Hepatol.
- 2023 Jul;29(3):705-720.
- doi: 10.3350/cmh.2023.0004
Background/Aims: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
-
Lin CL, Kao JH
- KMID: 2543983
- Clin Mol Hepatol.
- 2023 Jul;29(3):605-622.
- doi: 10.3350/cmh.2022.0342
Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved... -
- CITED
-
- Close
- SHARE
-
- Close
